Journal article

Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE epsilon 4, sex and age

Scott Ayton, Shorena Janelidze, Blaine Roberts, Sebastian Palmqvist, Pawel Kalinowski, Ibrahima Diouf, Abdel A Belaidi, Erik Stomrud, Ashley Bush, Oskar Hansson

PROGRESS IN NEUROBIOLOGY | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2021

Abstract

It is unknown how neuroinflammation may feature in the etiology of Alzheimer's disease (AD). We profiled acute phase response (APR) proteins (α1-antitrypsin, α1-antichymotrypsin, ceruloplasmin, complement C3, ferritin, α-fibrinogen, β-fibrinogen, γ-fibrinogen, haptoglobin, hemopexin) in CSF of 1291 subjects along the clinical and biomarker spectrum of AD to investigate the association between inflammatory changes, disease outcomes, and demographic variables. Subjects were stratified by Aβ42/t-tau as well as the following clinical diagnoses: cognitively normal (CN); subjective cognitive decline (SCD); mild cognitive impairment (MCI); and AD dementia. In separate multiple regressions (adjustin..

View full abstract

Grants

Funding Acknowledgements

This study was supported by a grant from the BAND consortium: Alzheimer's Association, Westin Brain Institute, Michael J Fox Foundation, Alzheimer's Research UK. Fellowship support from the National Health & Medical Research Council of Australia. Alzheimer's Drug discovery foundation, Cooperative Research Centre for Mental Health. Fellowship support from the National Health & Medical Research Council of Australia. The Victorian Government's Operational Infrastructure Support Program. We would like to thank the Florey Neuroproteomics Facility. BioFINDER is funded by the Swedish Research Council, the Knut and Alice Wallenberg foundation, the Marianne and Marcus Wallenberg foundation, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation, the Swedish Brain Foundation, The Parkinson foundation of Sweden, The Parkinson Research Foundation, the Skane University Hospital Foundation, and the Swedish federal government under the ALF agreement.